Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Number One Question For Valeant: What Next?

This article was originally published in The Pink Sheet Daily

Executive Summary

Now that the hostile bid for Cephalon has fallen through, Valeant's CEO sees "no shortage of exciting opportunities" but says there's no hurry.
Advertisement

Related Content

Valeant’s Latest M&A Gambit Hits Snag With Ista’s Rejection Of $314 Million Buyout Offer
Valeant Adds To Dermatology Business By Acquiring Sanofi's Dermik For $425 Million
Valeant Adds To Dermatology Business By Acquiring Sanofi's Dermik For $425 Million
Valeant Expands Dermatology In Staged Deal With Meda
Valeant Expands Dermatology In Staged Deal With Meda
In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio
In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio
Tax Benefits Highlight Announced Merger Of Valeant And Biovail

Topics

Advertisement
UsernamePublicRestriction

Register

PS072343

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel